Tango Therapeutics (NASDAQ: TNGX) saw its shares skyrocket more than 51% on Monday, following the release of promising early-stage clinical data for its experimental cancer therapy, vopimetostat. The sharp rally pushed the stock near a record closing high, marking one of its strongest single-day performances in over a year, as investors responded to results that could reshape treatment options for pancreatic cancer, one of the most lethal malignancies.
The data came from an ongoing Phase 1/2 study evaluating vopimetostat in combination with Revolution Medicines' daraxonrasib, as well as with zoldonrasib, in patients with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer (NSCLC).
Pancreatic Cancer Data Exceeds Expectations
According to the company, the combination of vopimetostat and daraxonrasib produced a 92% objective response rate (ORR) in pancreatic cancer patients, meaning tumors shrank or disappeared in 11 out of 12 evaluable participants. The study also reported a 90% progression-free survival rate at six months and 100% disease control, indicating that nearly all patients experienced either tumor reduction or disease stabilization.
In a small cohort of NSCLC patients, the same combination yielded a 100% response rate. A separate arm combining vopimetostat with zoldonrasib generated a 52% ORR, a 74% six-month progression-free survival rate, and a 96% disease control rate in pancreatic cancer patients. Importantly, the company noted that the treatment combinations were generally well tolerated, with few major side effects and no treatment-related Grade 4 or Grade 5 adverse events observed.
“The results from our ongoing combination trial dramatically exceeded our expectations,” said Tango Therapeutics CEO Malte Peters on a conference call Monday. He added that the company’s “primary focus is now to bring forward” the vopimetostat and daraxonrasib combination “approach in pancreatic cancer.” The findings support advancing the combination into a larger Phase 3 study as a potential first-line, chemotherapy-free treatment for newly diagnosed pancreatic cancer patients by the end of 2026.
Analysts Turn More Optimistic
Wall Street responded positively, with several firms raising price targets and reiterating bullish ratings. Wolfe Research upgraded Tango Therapeutics to “Outperform” from “Peer Perform” and assigned a $35 price target. Analyst Kalpit Patel described the findings as “groundbreaking with no major red flags.” The firm also increased its estimate for vopimetostat’s unadjusted global peak sales potential to approximately $2.6 billion from $1.9 billion while raising its probability of success.
Mizuho analyst Joseph Catanzaro maintained an “Outperform” rating and raised his price target to $36 from $30, stating the data “starts to tell a potentially very compelling signal of improved long-term outcomes.” B. Riley Securities analyst Yuan Zhi also raised his price target to $35 from $21 while maintaining a Buy rating, calling the 92% ORR “unprecedented” and adding that the early results leave Tango Therapeutics “undervalued at current levels.”
Overall, analysts appear broadly optimistic. According to FactSet data, the company carries an average Buy rating among Wall Street firms, with an average price target of approximately $35.09.
Focus Shifts to Late-Stage Development
While the study remains relatively small and lacks a comparison group, Monday’s update adds to growing industry enthusiasm surrounding daraxonrasib and the broader effort to improve outcomes for pancreatic cancer patients. Tango also highlighted additional pipeline opportunities, with Peters noting that future data releases involving vopimetostat as a standalone treatment in lung cancer and its TNG456 therapy in glioblastoma represent “significant long-term opportunity” for the company.
The latest findings have strengthened investor confidence that vopimetostat could evolve into a late-stage pancreatic cancer program, particularly as the company prepares for larger clinical trials. As Tango moves toward Phase 3 testing, investors will be watching closely to see whether the promising early data can be replicated in larger studies.
For context on broader market movements, see our coverage of the Dow's recent rally and the Madison Air IPO surge. Additionally, the biotech sector has seen notable activity, as highlighted in our report on Eli Lilly's obesity drug pipeline.
This article is for informational purposes only and does not constitute financial advice.
